Study examined the cost effectiveness of brentuximab vedotin combined with chemotherapy for first line treatment of Hodgkin lymphoma.
Home / Resource Library / Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis